公开(公告)号：US20240363194A1

公开(公告)日：2024-10-31

申请号：US18764600

申请日：2024-07-05

申请人： A-Alpha Bio

发明人： Ryan Emerson ,  Randolph Lopez ,  David Younger

IPC分类号： G16B15/30 ,  C12N15/10 ,  G16B35/20

CPC分类号： G16B15/30 ,  C12N15/1037 ,  G16B35/20

摘要： The present disclosure provides methods for improving libraries for screening protein-protein interactions (PPI) by excluding amino acid substitutions that are predicted to have a redundant or minimal effect on binding between protein binding partners.

公开(公告)号：US20240360410A1

公开(公告)日：2024-10-31

申请号：US18294795

申请日：2022-08-02

申请人： SUZHOU GRIT BIOTECHNOLOGY CO., LTD. ,  ZHUHAI TUOYU BIOTECHNOLOGY CO., LTD. ,  SHANGHAI GRIT BIOTECHNOLOGY CO., LTD. ,  SHENZHEN GRIT BIOTECHNOLOGY CO., LTD.

发明人： Yarong LIU ,  Jingwei SUN ,  Yao SHENG

IPC分类号： C12N5/0783 ,  A61K35/17 ,  C12N9/22 ,  C12N15/10 ,  C12N15/11

CPC分类号： C12N5/0636 ,  A61K35/17 ,  C12N9/22 ,  C12N15/102 ,  C12N15/111 ,  C12N2501/2302 ,  C12N2501/998 ,  C12N2502/1157

摘要： Provided are a modified tumor infiltrating lymphocyte (TIL) and a use thereof. Also provided is a method for culturing the TIL, comprising reducing the expression and/or decreasing the activity of NF-κB pathway inhibitory molecules of the TIL. Further provided is a method for preventing and/or treating tumors by using the TIL.

公开(公告)号：US12129463B2

公开(公告)日：2024-10-29

申请号：US18125075

申请日：2023-03-22

申请人： Encodia, Inc.

发明人： Mark S. Chee ,  Kevin L. Gunderson ,  Michael Phillip Weiner ,  Lei Shi ,  Norihito Muranaka

IPC分类号： C12N15/10 ,  C12Q1/6804 ,  G01N33/68

CPC分类号： C12N15/1065 ,  C12Q1/6804 ,  G01N33/68 ,  G01N2458/10

摘要： Methods and Kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and/or nucleic acid recording of a molecular interaction and/or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Assays that do not require the cyclic transfer of information between a coding tag and a recording tag are also disclosed, including single cycle assays.

公开(公告)号：US20240355419A1

公开(公告)日：2024-10-24

申请号：US18640635

申请日：2024-04-19

申请人： UT-Battelle, LLC

发明人： Xiaohan Yang ,  Md Mahmudul Hassan ,  Stanton Martin ,  Gerald A. Tuskan ,  Guoliang Yuan

IPC分类号： G16B25/20 ,  C12N9/22 ,  C12N15/10 ,  C12N15/11 ,  G16B35/20

CPC分类号： G16B25/20 ,  C12N9/22 ,  C12N15/1096 ,  C12N15/111 ,  G16B35/20 ,  C12N2310/121 ,  C12N2310/123 ,  C12N2310/20 ,  C12Y301/26005 ,  C12Y301/26011

摘要： The present disclosure is directed to polycistronic guide RNAs, DNA encoding polycistronic gRNA, multiplex CRISPR vectors, a plurality of component DNA fragments for assembly into a DNA encoding a polycistronic gRNA array, a plurality of primer pairs for making a plurality of component DNA fragments to be assembled into a DNA encoding a polycistronic gRNA, and methods of making multiplex CRISPR vectors. The current disclosure is directed to multiplexed CRISPR technologies that have great potential for pathway engineering and genome editing. In the current disclosure describes efficient assembly of tRNA/Csy4/Ribozyme-based gRNA arrays which can be produced in a quick and effective process.

公开(公告)号：US20240352445A1

公开(公告)日：2024-10-24

申请号：US18683502

申请日：2022-08-15

申请人： ABWIZ BIO, INC.

发明人： Toshiaki MARUYAMA ,  Shigeru CJ Okumura ,  Kevin ENTZMINGER

IPC分类号： C12N15/10 ,  C07K16/10 ,  G01N33/68

CPC分类号： C12N15/1037 ,  C07K16/1003 ,  C12N15/1058 ,  G01N33/6845

摘要： The present disclosure discloses a method for identifying an optimized protein. The method involves constructing and targeting targeted libraries against a target antigen using a first set of selection conditions to select a pool of binders in each library, combining the selected libraries into one or more libraries; and selecting the combined library against the target antigen using a second set of selection conditions to identify at least one protein having an optimized functional profile. An exemplar protein that can be identified with this method is an antibody or a fragment thereof.

公开(公告)号：US20240352443A1

公开(公告)日：2024-10-24

申请号：US18686319

申请日：2022-07-22

申请人： DNA Script

发明人： Sandrine CRETON ,  Florence MAHE

IPC分类号： C12N15/10 ,  C12N9/00 ,  C12N9/22

CPC分类号： C12N15/1031 ,  C12N9/22 ,  C12N9/93 ,  C12Y605/01001

摘要： The present invention relates to a method for generating a double-stranded nucleic acid having a predetermined sequence and a method for producing a double-stranded polynucleotide of interest. The invention further relates to a kit for the implementation of said methods.

公开(公告)号：US20240352442A1

公开(公告)日：2024-10-24

申请号：US18137786

申请日：2023-04-21

申请人： Zhejiang Difference Biological Technology Co., Ltd.

发明人： Shuihua MAO ,  Mengyun ZHOU ,  Ruiting CHEN ,  Xiaofei LIU ,  Jiasheng SONG

IPC分类号： C12N15/10 ,  C12N7/04

CPC分类号： C12N15/102 ,  C12N7/04 ,  C12N2760/16121

摘要： The present disclosure relates to a method for attenuating an influenza virus, an attenuated influenza virus strain and use thereof, and belongs to the technical field of attenuated vaccines. In the present disclosure, the method includes the following steps: conducting synonymous mutation on an overlap of an M2 gene and an M1 gene in an M gene of an influenza A virus, while ensuring integrity and invariance of an amino acid sequence encoded by the M1 gene; conducting mutation into termination codon and deletion of partial nucleotide sequence in a transmembrane domain of the M2 gene, and rescuing an attenuated influenza virus strain using a reverse genetic system.

公开(公告)号：US12123014B2

公开(公告)日：2024-10-22

申请号：US18302387

申请日：2023-04-18

申请人： METAGENOMI, INC.

发明人： Brian Thomas ,  Christopher Brown ,  Audra Devoto ,  Cristina Butterfield ,  Lisa Alexander ,  Daniela S. A. Goltsman ,  Justine Albers ,  Alan Brooks ,  Greg Cost ,  Morayma Temoche-Diaz ,  Cindy Castelle ,  Rebecca Lamothe

IPC分类号： C12N15/90 ,  C12N9/22 ,  C12N15/10 ,  C12N15/11

CPC分类号： C12N15/90 ,  C12N9/22 ,  C12N15/1068 ,  C12N15/11 ,  C12N15/111 ,  C12N15/902 ,  C12N15/907 ,  C12N2310/20 ,  C12N2800/80

摘要： Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

公开(公告)号：US12121586B2

公开(公告)日：2024-10-22

申请号：US17129251

申请日：2020-12-21

申请人： Genentech, Inc.

发明人： Patrick Koenig ,  Chingwei Vivian Lee ,  Karthikan Rajagopal ,  Amin Famili ,  Germaine Fuh

IPC分类号： C40B30/04 ,  A61K39/395 ,  A61K47/34 ,  A61K47/60 ,  A61K47/61 ,  C07K14/475 ,  C07K16/22 ,  C07K16/44 ,  C07K16/46 ,  C12N15/10 ,  C12N15/115 ,  A61K39/00

CPC分类号： A61K47/61 ,  A61K39/3955 ,  A61K47/34 ,  A61K47/60 ,  C07K14/475 ,  C07K16/22 ,  C07K16/44 ,  C07K16/468 ,  C12N15/1037 ,  C12N15/115 ,  C40B30/04 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2318/20 ,  C07K2319/30 ,  C07K2319/31 ,  C12N2310/16

摘要： The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

公开(公告)号：US20240344942A1

公开(公告)日：2024-10-17

申请号：US18631687

申请日：2024-04-10

申请人： JICHI MEDICAL UNIVERSITY ,  EIKEN KAGAKU KABUSHIKI KAISHA

发明人： Kazutaka FUJITA ,  Koichi HAGIWARA

IPC分类号： G01N1/30 ,  C12N15/10 ,  C12Q1/6886

CPC分类号： G01N1/30 ,  C12N15/1003 ,  C12Q1/6886

摘要： A method for preparing a sample from a specimen includes treating a biopsy tissue taken from a lung cancer patient with negative pressure in an isotonic solution to release a cell from the biopsy tissue, collecting the isotonic solution containing the released cell, and mixing the collected isotonic solution and a cytologic specimen collected from the lung cancer patient together to obtain a cell suspension, wherein the cytologic specimen is one or more selected from the group consisting of a bronchial lavage fluid, a bronchoalveolar lavage fluid, a bronchial scraping lavage fluid and a puncture needle lavage fluid, and wherein the biopsy tissue and the cytologic specimen contain a tumor cell.